Business Context and Reporting Period
Company: iBio, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Six months ended December 31, 2010
Business Overview: iBio is a biotechnology company focused on commercializing its proprietary iBioLaunch platform for producing biologics, including vaccines (H1N1, H5N1) and therapeutic proteins. The company has no product revenue and relies on licensing arrangements and equity financing.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2010 | Six Months Ended Dec 31, 2009 |
|---|---|---|
| Revenue (Sales) | $0 | $0 |
| Net Loss | $(7,528,392) | $(1,851,033) |
| Net Loss Per Share (Basic/Diluted) | $(0.25) | $(0.07) |
| Operating Cash Flow | $(2,231,230) | $(487,303) |
| Cash and Cash Equivalents (Ending) | $5,768,766 | $3,001,016 |
| Total Assets | $10,416,268 | $4,930,245 |
| Total Liabilities | $8,240,930 | $3,854,115 |
| Derivative Instrument Liability | $5,994,703 | $1,714,084 |
| Stockholders' Equity | $2,175,338 | $1,076,130 |
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased by approximately 307% to $7.53 million, driven primarily by a non-cash expense of $4.28 million related to the change in fair value of derivative instrument liabilities.
- Operating Expenses: Total operating expenses rose to $3.23 million from $1.33 million. Research and Development (R&D) increased 117% to $777,000, and General and Administrative (G&A) expenses increased 153% to $2.46 million. Increases were largely due to personnel costs and stock-based compensation.
- Liquidity Improvement: Cash balances increased by $4.86 million, primarily due to net proceeds of $7.24 million from a private equity offering completed in October and November 2010.
- Derivative Liability: The liability associated with warrants issued in 2008 increased significantly from $1.71 million to $5.99 million due to an increase in the company's stock price, resulting in a substantial non-cash charge.
Guidance, Outlook, and Risks
- Capital Resources: Management expects current cash and working capital to support operations through the end of calendar 2011. Funding for 2012 and beyond is planned via licensing or additional equity sales.
- Going Concern: The financial statements are prepared under the assumption of a going concern, which is dependent on the ability to obtain additional financing. Failure to secure funding could force the company to delay development or relinquish technology rights.
- Forward-Looking Risks: Significant risks include the volatility of the derivative liability (which fluctuates with stock price), the inability to generate revenue from the iBioLaunch platform, and the potential for significant shareholder dilution in future financing rounds.
- Unusual Items: The $4.28 million non-cash expense related to derivative instruments is a material non-operating item that significantly distorts the net loss relative to cash burn.
Investor Verification Checklist
- Runway: Verify if the $5.77 million cash balance is sufficient to cover the projected burn rate through 2011, given the increased operating expenses.
- Derivative Liability: Monitor the company's stock price volatility, as increases will directly inflate the non-cash derivative liability and reported net loss.
- Financing Needs: Assess the likelihood and terms of future equity raises required for 2012, noting the risk of dilution.
- Revenue Generation: Confirm progress on licensing agreements or commercialization of the H1N1/H5N1 vaccine candidates, as the company currently has zero revenue.
- Commitments: Review the $10 million commitment to FhCMB (Fraunhofer USA) for R&D services and ensure cash flow can support these contractual obligations.